ProKidney Corp. (BMV:PROK)

Mexico flag Mexico · Delayed Price · Currency is MXN
46.33
+3.63 (8.50%)
At close: Dec 4, 2025
28.69%
Market Cap 6.63B
Revenue (ttm) 13.65M
Net Income (ttm) -1.30B
Shares Out n/a
EPS (ttm) -9.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 15,508
Average Volume 24,747
Open 45.40
Previous Close 42.70
Day's Range 45.40 - 46.33
52-Week Range 12.18 - 132.00
Beta n/a
RSI 41.03
Earnings Date Nov 12, 2025

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2015
Employees 204
Stock Exchange Mexican Stock Exchange
Ticker Symbol PROK
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.